A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/2/2019
Start Date:June 29, 2018
End Date:September 14, 2021
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of the study is to characterize safety of JNJ-68284528 and establish the
recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528
(Phase 2).

This study will evaluate the safety and efficacy of JNJ-68284528. The study will include two
phases. In Phase1b the study will enroll adults with multiple myeloma with interval
assessments for potential dose escalation or de-escalation in subsequent participants. The
dose selected at the completion of phase 1b will be used in Phase 2. Following consent,
enrolled participants will undergo an apheresis procedure to collect cells for manufacture of
investigational drug product (JNJ-68284528). Following manufacture of the drug product,
participants will undergo lymphodepletion prior to infusion of JNJ-68284528. Participants
will be followed for at least 2 years after study drug infusion, with long-term 15 year
follow-up on a separate study. The study will evaluate safety, biomarkers,
pharmacokinetic/pharmacodynamic evaluations and efficacy.

Inclusion Criteria:

- Have documented diagnosis of multiple myeloma according to International Myeloma
Working Group (IMWG) diagnostic criteria

- Have measurable disease at Screening as defined by any of the following a) Serum
monoclonal paraprotein (M-protein) level more than or equal to (>=) 1.0 gram per
deciliter(g/dL) or urine M-protein level >=200 milligram per 24 hours (mg/24hr); or b)
Light chain multiple myeloma without measurable disease in the serum or the urine:
Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa
lambda free light chain ratio

- Have received at least 3 prior multiple myeloma treatment regimens or are double
refractory to an immunomodulatory drug (IMiD) and proteasome inhibitor (PI)
(refractory multiple myeloma as defined by IMWG consensus criteria). Note: induction
with or without hematopoietic stem cell transplant and with or without maintenance
therapy is considered a single regimen a) Undergone at least 1 complete cycle of
treatment for each regimen, unless progressive disease (PD) was the best response to
the regimen

- Have received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody

- Have documented disease progression within 12 months of starting the most recent
anti-myeloma therapy

- Have Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1

Exclusion Criteria:

- Have received prior treatment with chimeric antigen receptor T (CAR-T) therapy
directed at any target

- Have received any therapy that is targeted to B-cell maturation antigen (BCMA)

- Have following cardiac conditions: a) New York Heart Association (NYHA) stage III or
IV congestive heart failure b) Myocardial infarction or coronary artery bypass graft
(CABG) 6 months prior to enrollment c) History of clinically significant ventricular
arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to
dehydration d) History of severe non-ischemic cardiomyopathy e) Impaired cardiac
function (left ventricular ejection fraction [LVEF] less than [<]45%) as assessed by
echocardiogram or multiple-gated acquisition (MUGA) scan (performed 8 weeks of
apheresis)

- Have systemic corticosteroid therapy of greater than 5 mg/day of prednisone (or
equivalent dose of another corticosteroid) within 2 weeks prior to apheresis

- Have received either of the following: a) An allogenic stem cell transplant within 6
months before apheresis. Participants who received an allogeneic transplant must be
off all immunosuppressive medications for 6 weeks without signs of graft-versus-host
disease (GVHD) b) An autologous stem cell transplant 12 weeks before apheresis

- Have known active central nervous system (CNS) involvement or exhibits clinical signs
of meningeal involvement of multiple myeloma
We found this trial at
17
sites
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Antwerp,
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
9200 West Wisconsin Avenue
Milwaukee, Wisconsin 53226
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials